European Neuropsychopharmacology
Volume 20, Issue 6 , Pages 421-425 , June 2010

The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats

  • Martin Weber

      Affiliations

    • Department of Psychiatry, UCSD School of Medicine, USA
    • ,
  • Wei-Li Chang

      Affiliations

    • Department of Psychiatry, UCSD School of Medicine, USA
    • ,
  • Michelle R. Breier

      Affiliations

    • Department of Psychiatry, UCSD School of Medicine, USA
    • ,
  • Alex Yang

      Affiliations

    • Department of Psychiatry, UCSD School of Medicine, USA
    • ,
  • Mark J. Millan

      Affiliations

    • Institut de Recherches Servier, France
    • ,
  • Neal R. Swerdlow

      Affiliations

    • Department of Psychiatry, UCSD School of Medicine, USA
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, UCSD School of Medicine, 9500 Gilman Dr., La Jolla, CA 92093-0804, USA. Tel.: +1 619 543 6270; fax: +1 619 543 1801.

Received 25 November 2009 ,Accepted 26 February 2010.

References 

  1. Achat-Mendes C, Platt DM, Newman AH, Spealman RD. The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys. Psychopharmacology. 2009;206:73–84
  2. Chang WL, Saint Marie RL, Miller E, Weber M, Swerdlow NR. Effects of the D3/D2 agonist, pramipexole, on sensorimotor gating and nucleus accumbens signaling in the rat. Biol. Psychiatry. 2009;65:76s
  3. Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C, et al. Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology. 2007;193:159–170
  4. Cussac D, Newman-Tancredi A, Sezgin L, Millan MJ. The novel antagonist, S33084, and GR218, 231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors. Eur. J. Pharmacol. 2000;394:47–50
  5. de Paulis T. Sumanirole Pharmacia. Curr. Opin. Investig. Drugs. 2003;4:77–82
  6. Heier RF, Dolak LA, Duncan JN, Hyslop DK, Lipton MF, Martin IJ, et al. Synthesis and biological activities of (R)-5, 6-dihydro-N, N-dimethyl-4H-imidazo[4, 5, 1-ij]quinolin-5-amine and its metabolites. J. Med. Chem. 1997;40:639–646
  7. Koffarnus MN, Greedy B, Husbands SM, Grundt P, Newman AH, Woods JH. The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats. Psychopharmacology. 2008;203:317–327
  8. McCall RB, Lookingland KJ, Bedard PJ, Huff RM. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2005;314:1248–1256
  9. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218, 231 and L741, 626. J. Pharmacol. Exp. Ther. 2000;293:1048–1062
  10. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 2002;303:791–804
  11. Millan MJ, Seguin L, Gobert A, Cussac D, Brocco M. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology. 2004;174:341–357
  12. Saint Marie RL, Neary AC, Shoemaker J, Swerdlow NR. Apomorphine effects on CREB phosphorylation in the nucleus accumbens of rat strains that differ in PPI sensitivity. Biol. Psychiatry. 2007;61:37s
  13. Swerdlow NR, Shoemaker JM, Auerbach PP, Pitcher L, Goins J, Platten A. Heritable differences in the dopaminergic regulation of sensorimotor gating. II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology. 2004;174:452–462
  14. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology. 2008;199:331–388
  15. Swerdlow NR, Lelham SA, Sutherland Owens AN, Chang WL, Sassen SD, Talledo JA. Pramipexole effects on startle gating in rats and normal men. Psychopharmacology. 2009;205:689–698
  16. Wadenberg MG, Sills TL, Fletcher PJ, Kapur S. Antipsychoticlike effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats. Biol. Psychiatry. 2000;47:670–676
  17. Weber M, Chang WL, Breier M, Ko D, Swerdlow NR. Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav. Pharmacol. 2008;19:786–795
  18. Weber M, Chang WL, Durbin JP, Park PE, Luedtke RR, Mach RH, et al. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacol. Biochem. Behav. 2009;93:141–147
  19. Wuts PGM, Gu RL, Northuis JM, Kwan TA, Beck DM, White MJ. Development of a practical synthesis of sumanirole. Pure Appl. Chem. 2002;74:1359–1368
  20. Zhang M, Ballard ME, Unger LV, Haupt A, Gross G, Decker MW, et al. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behav. Brain Res. 2007;182:1–11

PII: S0924-977X(10)00044-1

doi: 10.1016/j.euroneuro.2010.02.011

European Neuropsychopharmacology
Volume 20, Issue 6 , Pages 421-425 , June 2010

Article Tools

* Image Usage & Resolution